Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 12345 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke.DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER, BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Deans' stroke musings
Changing stroke rehab and research worldwide now.Time is Brain!Just think of all thetrillions and trillions of neuronsthateach daybecause there areeffective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group. My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html
Saturday, February 18, 2017
Little-known disease has major economic impact - Giant cell arteritis
Giant cell arteritis is estimated to cost U.S. healthcare system $1 billion in first year of treatment.
Healthcare system spending on patients in the United States with giant
cell arteritis is $16,400 more in the first year after diagnosis
compared to similar patients without the disease. This finding comes
from a new study from the University of Washington School of Public
Health. The little–known, chronic disease of the blood vessels affects
“In addition to its significant clinical burden, giant cell arteritis
has a substantial economic impact, as it increases costs to both the
health care system and patients in the U.S.,” said Joseph Babigumira,
lead author of the study. He is an assistant professor of global health
and adjunct assistant professor of pharmacy.
“It is estimated that nearly 950,000 individuals will be diagnosed with
giant cell arteritis and 140,000 will become visually impaired because
of giant cell arteritis in the U.S. between 2014 and 2050,” the
researchers wrote, citing previous research.
To estimate the cost of illness among patients with the disease,
researchers used a national sample of claims data from the Truven Health
Analytics MarketScan databases for the years 2007–2013. They also
looked at data from the Medicare supplemental database.
Researchers compared the health care costs of 1,293 patients recently
diagnosed with giant cell arteritis to that of a control group of 6,465
enrollees who did not have the chronic disease.
The findings were published online Jan. 13 in the journal Rheumatology
and Therapy. The results showed that the “mean one–year cost for giant
cell arteritis patients was $34,065 and mean one–year cost for controls
was $12,890.” After adjusting for multiple variables, the difference in
cost was $16,431.
What’s more, patients with giant cell arteritis spent an average of more
than $5,000 in additional inpatient costs, more than $10,000 in
additional outpatient costs and $660 in additional pharmacy costs.
Total health care cost associated with giant cell arteritis in the first
year following diagnosis in the U.S. is higher than that of non–cystic
fibrosis bronchiectasis, systemic lupus erythematosus and endometriosis,
but lower than costs associated with breast cancer.
“Given the annual incidence of 18.9 giant cell arteritis cases per
100,000 population in the U.S., the first–year aggregate cost of giant
cell arteritis following diagnosis is estimated to be nearly one billion
dollars in the U.S.,” researchers wrote.
“Effective therapies are needed to reduce the impact of giant cell
arteritis on morbidity, and have the potential to reduce the cost burden
of the complications associated with the disease,” Babigumira said.